Wells Fargo keeps USD 50.00 target for Omnicell stock

Published on 10/17/2026 at 19:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 312.21 million, up 7.40 percent year over year. Omnicell stock last traded at USD 35.39 on October 16, 2026, down 1.56 percent on Nasdaq.

Analyst target and results

Wells Fargo maintained its USD 50.00 target on October 14, 2026.
Second-quarter revenue reached USD 312.21 million, up 7.40 percent year over year.
Omnicell stock last traded at USD 35.39 on Nasdaq on October 16, 2026, down 1.56 percent from USD 35.95.
Omnicell will publish third-quarter 2026 results on October 29, 2026.

OMCL, US68213N1090, Illustration mit AI erstellt.

Wells Fargo maintained a Buy rating and a USD 50.00 price target for Omnicell on October 14, 2026, according to Markets Insider. The target is 41.28 percent above the last Nasdaq price of USD 35.39. Omnicell stock last traded at USD 35.39 on October 16, 2026 at 4:00 p.m. ET, down 1.56 percent from the Nasdaq prior close of USD 35.95.

Revenue reached USD 312.21 million

Omnicell generated USD 312.21 million in revenue in the second quarter of 2026, up 7.40 percent from the year-ago quarter. Net income attributable to common shareholders was USD 24.29 million, while diluted earnings per share came to USD 0.52.

The quarterly figures show a sharper operating improvement than in the first quarter of 2026. Revenue rose from USD 309.88 million to USD 312.21 million, while operating profit increased from USD 16.85 million to USD 32.45 million.

What does the price position show?

Omnicell traded between its 52-week low of USD 29.09 and high of USD 55.00 as of October 16, 2026. The last price was 21.66 percent above the low and 35.65 percent below the high. Market capitalization stood at USD 1.6 billion, with a trailing P/E ratio of 41.89.

October 29 results date

Omnicell will release its third-quarter 2026 results before the Nasdaq open on October 29, 2026, followed by a conference call at 8:30 a.m. ET, according to Omnicell. MarketBeat lists consensus expectations of USD 0.42 in earnings per share and USD 304.43 million in revenue for the quarter.

Comparison with peers

Omnicell (Nasdaq, USD): minus 1.56 percent, P/E 41.89, market capitalization USD 1.6 billion

Becton, Dickinson and Company (NYSE, USD): minus 1.04 percent, P/E 57.76, market capitalization USD 52.2 billion

McKesson (NYSE, USD): plus 0.62 percent, P/E 26.89, market capitalization USD 117.2 billion

Trading levels and valuation

The comparison places Omnicell below the larger healthcare distributors by market value, while its P/E of 41.89 is above McKesson's 26.89 and below Becton, Dickinson and Company's 57.76. The next dated company event is the October 29 results release, which should provide the next reported operating figures.

Omnicell supplies medication-management technology, automation systems and software for hospitals, health systems and pharmacies. Its solutions combine hardware, software and services across pharmacy and nursing workflows.

Omnicell stock last traded at USD 35.39 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 1.56 percent from the Nasdaq prior close of USD 35.95.